CS
TYRA icon

Credit Suisse’s Tyra Biosciences TYRA Stock Holding History

Credit Suisse’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$8 – 3711
2022
Q4 		$8 Sell
1
-72
-99% -$509 ﹤0.01% 3767
2022
Q3 		$1K Buy
73
+39
+115% +$357 ﹤0.01% 3937
2022
Q2 		$0 Buy
+34
New +$271 ﹤0.01% 4325

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's TYRA Position: Q1 2023 in Review

Credit Suisse sold out of Tyra Biosciences (TYRA) in Q1 2023, closing a stake of 1 share — an estimated $8 sold.

Credit Suisse first reported a position in TYRA in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 51 funds tracked by Wall St. Rank hold TYRA as of Q1 2023.

  • Credit Suisse reported no remaining Tyra Biosciences position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Tyra Biosciences share in Q1 2023, an estimated $8.
  • Credit Suisse first reported a position in Tyra Biosciences in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Tyra Biosciences position peaked at $1K in Q3 2022.
  • 51 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.